Shell Asset Management CO Supernus Pharmaceuticals, Inc. Transaction History

Shell Asset Management CO

$2.9 Billion
Q2 2025

A detailed history of Shell Asset Management CO transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 7,611 shares of SUPN stock, worth $250,021. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,611

Previous 9,051 15.91%

Holding current value

$250,021

Previous $296,000 18.92%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$30.29 - $33.43 $43,617 - $48,139	-1,440 Reduced 15.91%	7,611 $240,000
Q1 2025 May 14, 2025	SELL	$31.17 - $40.0 $9,070 - $11,640	-291 Reduced 3.11%	9,051 $296,000
Q3 2024 Nov 07, 2024	SELL	$25.77 - $35.16 $13,761 - $18,775	-534 Reduced 5.41%	9,342 $291,000
Q1 2024 Jul 31, 2024	SELL	$27.11 - $35.17 $16,862 - $21,875	-622 Reduced 5.92%	9,876 $264,000
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $9,976 - $12,942	-368 Reduced 3.39%	10,498 $358,000
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $74,544 - $97,380	-3,281 Reduced 23.19%	10,866 $314,000
Q3 2023 Nov 08, 2023	SELL	$27.57 - $32.91 $6,727 - $8,030	-244 Reduced 1.7%	14,147 $390,000
Q2 2023 Jul 28, 2023	SELL	$29.91 - $38.73 $2,422 - $3,137	-81 Reduced 0.56%	14,391 $433,000
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $1,746 - $2,101	-50 Reduced 0.34%	14,472 $524,000
Q4 2022 Feb 07, 2023	SELL	$31.09 - $37.88 $96,503 - $117,579	-3,104 Reduced 17.61%	14,522 $518,000
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $132,606 - $163,098	-4,606 Reduced 20.72%	17,626 $597,000
Q2 2022 Aug 09, 2022	BUY	$25.33 - $34.25 $1,139 - $1,541	45 Added 0.2%	22,232 $643,000
Q1 2022 May 04, 2022	SELL	$28.51 - $32.9 $93,541 - $107,944	-3,281 Reduced 12.88%	22,187 $717,000
Q4 2021 Feb 09, 2022	BUY	$26.37 - $34.22 $2,847 - $3,695	108 Added 0.43%	25,468 $743,000
Q3 2021 Nov 04, 2021	SELL	$23.54 - $31.39 $25,658 - $34,215	-1,090 Reduced 4.12%	25,360 $676,000
Q2 2021 Aug 12, 2021	BUY	$26.72 - $33.19 $38,209 - $47,461	1,430 Added 5.72%	26,450 $814,000
Q1 2021 May 10, 2021	BUY	$24.15 - $31.45 $115,267 - $150,110	4,773 Added 23.57%	25,020 $655,000
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $103,989 - $128,957	5,148 Added 34.09%	20,247 $422,000
Q2 2020 Aug 10, 2020	BUY	$17.09 - $24.89 $258,041 - $375,814	15,099 New	15,099 $359,000
Q3 2019 Nov 12, 2019	SELL	$25.47 - $33.37 $775,204 - $1.02 Million	-30,436 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$29.96 - $38.87 $20,702 - $26,859	-691 Reduced 2.22%	30,436 $1.01 Million
Q4 2018 Feb 13, 2019	SELL	$30.84 - $49.51 $80,184 - $128,726	-2,600 Reduced 7.71%	31,127 $1.03 Million
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $574,955 - $761,445	-13,465 Reduced 28.53%	33,727 $1.7 Million
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $113,204 - $153,634	-2,567 Reduced 5.16%	47,192 $2.82 Million
Q3 2017 Oct 20, 2017	BUY	$36.75 - $49.65 $1.83 Million - $2.47 Million	49,759	49,759 $1.99 Million

Others Institutions Holding SUPN

# of Institutions

303

Shares Held

60.7M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.76B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.

Account

Shell Asset Management CO Supernus Pharmaceuticals, Inc. Transaction History